BR112022026792A2 - COMPOUNDS FOR USE IN THE DIAGNOSIS AND/OR MONITORING OF FIBROSIS - Google Patents
COMPOUNDS FOR USE IN THE DIAGNOSIS AND/OR MONITORING OF FIBROSISInfo
- Publication number
- BR112022026792A2 BR112022026792A2 BR112022026792A BR112022026792A BR112022026792A2 BR 112022026792 A2 BR112022026792 A2 BR 112022026792A2 BR 112022026792 A BR112022026792 A BR 112022026792A BR 112022026792 A BR112022026792 A BR 112022026792A BR 112022026792 A2 BR112022026792 A2 BR 112022026792A2
- Authority
- BR
- Brazil
- Prior art keywords
- seq
- acid
- peptide
- fibrosis
- diagnosis
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 206010016654 Fibrosis Diseases 0.000 title abstract 3
- 238000003745 diagnosis Methods 0.000 title abstract 3
- 230000004761 fibrosis Effects 0.000 title abstract 3
- 238000012544 monitoring process Methods 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 239000002738 chelating agent Substances 0.000 abstract 3
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 abstract 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 abstract 2
- JVHROZDXPAUZFK-UHFFFAOYSA-N TETA Chemical compound OC(=O)CN1CCCN(CC(O)=O)CCN(CC(O)=O)CCCN(CC(O)=O)CC1 JVHROZDXPAUZFK-UHFFFAOYSA-N 0.000 abstract 2
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- DZTVAULYUGBHSF-UHFFFAOYSA-N 2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)N1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 DZTVAULYUGBHSF-UHFFFAOYSA-N 0.000 abstract 1
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Radiology & Medical Imaging (AREA)
- High Energy & Nuclear Physics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Nuclear Medicine (AREA)
Abstract
COMPOSTOS PARA USO NO DIAGNÓSTICO E/OU MONITORAMENTO DE FIBROSE. É fornecida uma composição compreendendo: (i) um composto de Fórmula I: (i), ou um sal farmaceuticamente aceitável do mesmo, e (ii) um nuclídeo M, ou um sal farmaceuticamente aceitável do composto de Fórmula I e/ou o nuclídeo M, em que C é um quelante selecionado do grupo que consiste em ácido 1,4,7,10-tetrazaciclododecano-1,4,7,10-tetracético (DOTA), ácido 1,4,7-triazaciclononano-1,4,7-triacético (NOTA), ácido 1,4,8,11-tetrazaciclotetradecano-1,4,8,11-tetracético (TETA), ácido dietilenotriaminopentacético (DTPA), desferrioxamina B (DFO), 1,4,7- Ácido triazaciclononano-1-glutárico-4,7-ácido acético (NOTAGA), ácido 2-[4,7,10-Tris(carboximetil)-1,4,7,10-tetraza-1-ciclododecil]glutárico (DOTAGA e um derivado de qualquer um dos quelantes anteriores, L (Fórmula L) é um ligante: (L), em que m é um número inteiro dentro do intervalo de 1 a 20 e X é NH ou C(O) e forma uma ligação amida, ou seja C(O)NH, com uma fração C(O) ou NH do quelante, p é 0 ou 1, Q é um peptídeo de SEQ ID NO: 1, um análogo de peptídeo de SEQ ID NO: 1 tendo pelo menos 88,8% identidade para SEQ ID NO. 1, e/ou um peptídeo da SEQ ID NO: 1, um análogo de peptídeo da SEQ ID NO: 1 tendo pelo menos 88,8% de identidade com a SEQ ID NO: 1 e no qual o COOH C-terminal pode ser substituído por CONH2, e M é selecionado do grupo que consiste em 68Ga, 18F, 64Cu, 44Sc, 89Zr, 111In, 67Ga, 99mTc, Mn, Gd, 177Lu e 86/90Y. A composição pode ser utilizada no diagnóstico e/ou monitoramento de fibrose.COMPOUNDS FOR USE IN THE DIAGNOSIS AND/OR MONITORING OF FIBROSIS. There is provided a composition comprising: (i) a compound of Formula I: (i) or a pharmaceutically acceptable salt thereof, and (ii) a nuclide M, or a pharmaceutically acceptable salt of the compound of Formula I and/or the nuclide M, wherein C is a chelator selected from the group consisting of 1,4,7,10-tetrazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7-triazacyclononane-1,4 acid ,7-triacetic acid (NOTA), 1,4,8,11-tetrazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA), diethylenetriaminepentacetic acid (DTPA), desferrioxamine B (DFO), 1,4,7- Triazacyclononane-1-glutaric acid-4,7-acetic acid (NOTAGA), 2-[4,7,10-Tris(carboxymethyl)-1,4,7,10-tetraza-1-cyclododecyl]glutaric acid (DOTAGA and a derivative of any of the above chelators, L (Formula L) is a linker: (L) where m is an integer within the range 1 to 20 and X is NH or C(O) and forms an amide bond , i.e. C(O)NH, with a C(O) or NH fraction of the chelator, p is 0 or 1, Q is a peptide of SEQ ID NO: 1, an analog peptide group of SEQ ID NO: 1 having at least 88.8% identity to SEQ ID NO. 1, and/or a peptide of SEQ ID NO: 1, a peptide analogue of SEQ ID NO: 1 having at least 88.8% identity with SEQ ID NO: 1 and in which the C-terminal COOH can be replaced by CONH2, and M is selected from the group consisting of 68Ga, 18F, 64Cu, 44Sc, 89Zr, 111In, 67Ga, 99mTc, Mn, Gd, 177Lu and 86/90Y. The composition can be used in the diagnosis and/or monitoring of fibrosis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE2050786A SE545148C2 (en) | 2020-06-29 | 2020-06-29 | Novel compounds for use in diagnosis and/or monitoring of fibrosis |
| PCT/EP2021/067653 WO2022002834A1 (en) | 2020-06-29 | 2021-06-28 | Compounds for use in diagnosis and/or monitoring of fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022026792A2 true BR112022026792A2 (en) | 2023-01-17 |
Family
ID=76730567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022026792A BR112022026792A2 (en) | 2020-06-29 | 2021-06-28 | COMPOUNDS FOR USE IN THE DIAGNOSIS AND/OR MONITORING OF FIBROSIS |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230295227A1 (en) |
| EP (1) | EP4171663A1 (en) |
| JP (1) | JP2023532155A (en) |
| KR (1) | KR20230028412A (en) |
| CN (1) | CN115996761A (en) |
| AU (1) | AU2021298812A1 (en) |
| BR (1) | BR112022026792A2 (en) |
| CA (1) | CA3187298A1 (en) |
| SE (1) | SE545148C2 (en) |
| WO (1) | WO2022002834A1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015196208A2 (en) * | 2014-06-20 | 2015-12-23 | The General Hospital Corporation | Collagen targeted imaging probes |
| WO2018053276A1 (en) | 2016-09-16 | 2018-03-22 | Glycologix, Llc | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics |
| WO2019010485A1 (en) * | 2017-07-07 | 2019-01-10 | Symic Ip, Llc | Treatment of fibrosis |
| CN110129029A (en) * | 2019-02-14 | 2019-08-16 | 兰州大学 | A kind of single-stranded collagen polypeptide functional probe and preparation method thereof of electrical charge rejection effect induction |
| CN113710229A (en) * | 2019-02-25 | 2021-11-26 | 芝加哥大学 | Methods and compositions for treating inflammatory and autoimmune disorders with ECM affinity peptides linked to anti-inflammatory agents |
| CN110231327A (en) * | 2019-03-11 | 2019-09-13 | 兰州大学 | A kind of polypeptide Raman microprobe of targets identification collagen and its preparation and imaging method |
-
2020
- 2020-06-29 SE SE2050786A patent/SE545148C2/en unknown
-
2021
- 2021-06-28 WO PCT/EP2021/067653 patent/WO2022002834A1/en unknown
- 2021-06-28 BR BR112022026792A patent/BR112022026792A2/en unknown
- 2021-06-28 AU AU2021298812A patent/AU2021298812A1/en active Pending
- 2021-06-28 CA CA3187298A patent/CA3187298A1/en active Pending
- 2021-06-28 EP EP21736598.0A patent/EP4171663A1/en active Pending
- 2021-06-28 KR KR1020237002023A patent/KR20230028412A/en unknown
- 2021-06-28 US US18/010,904 patent/US20230295227A1/en active Pending
- 2021-06-28 CN CN202180046467.8A patent/CN115996761A/en active Pending
- 2021-06-28 JP JP2023523671A patent/JP2023532155A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022002834A1 (en) | 2022-01-06 |
| CN115996761A (en) | 2023-04-21 |
| AU2021298812A1 (en) | 2023-02-02 |
| EP4171663A1 (en) | 2023-05-03 |
| SE2050786A1 (en) | 2021-12-30 |
| JP2023532155A (en) | 2023-07-26 |
| KR20230028412A (en) | 2023-02-28 |
| SE545148C2 (en) | 2023-04-18 |
| US20230295227A1 (en) | 2023-09-21 |
| CA3187298A1 (en) | 2022-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2615805T3 (en) | Bombesin analog peptide antagonist conjugates | |
| US5925331A (en) | Technetium-99m labeled peptides for thrombus imaging | |
| US8304388B2 (en) | Imaging agents | |
| US8557776B2 (en) | Compounds and methods for 18F labeled agents | |
| PT2076535E (en) | Receptor(sstr2)-selective somatostatin antagonists | |
| NO179008B (en) | Analogous Process for the Preparation of Therapeutically Active Metal Complex Compounds | |
| JP2954355B2 (en) | Radioisotope labeled compounds for thrombus imaging | |
| US20020131932A1 (en) | Radiopharmaceuticals for diagnosing alzheimer's disease | |
| JPH11514329A (en) | Labeled peptide compounds | |
| CA2191949A1 (en) | Radiolabeled compounds for thrombus imaging | |
| US5776894A (en) | Chelated somatostatin peptides and complexes thereof, pharmaceutical compositions containing them and their use in treating tumors | |
| JP2005508886A5 (en) | ||
| JP2020534327A (en) | Minigastrin derivatives, especially minigastrin derivatives for use in the diagnosis and / or treatment of CCK2 receptor positive tumors | |
| BR112022026792A2 (en) | COMPOUNDS FOR USE IN THE DIAGNOSIS AND/OR MONITORING OF FIBROSIS | |
| Wester et al. | Radiolabeled carbohydrated somatostatin analogs: a review of the current status | |
| US5753627A (en) | Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis | |
| JP2014517005A5 (en) | ||
| EP0741747A1 (en) | Inhibitors of serine proteases, bearing a chelating group | |
| KR20240008341A (en) | Radiopharmaceutical somatostatin receptor ligands and precursors thereof | |
| US5952464A (en) | Labelled peptide compounds | |
| CA2429632A1 (en) | Neuropeptide y1 receptor binding compounds in the treatment and diagnosis of cancer | |
| HU221882B1 (en) | Complexes for diagnostics of vascular diseases | |
| AU633128B2 (en) | Anticoagulant peptides |